IGF-1 DES: molecular data, studies & sources

Molecular formula, weight & structure

Registered clinical trials

Studies registered on ClinicalTrials.gov that list des(1-3)IGF-I as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received des(1-3)IGF-I, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

1. Review · secondary evidence

   Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I.

   Ballard FJ, Wallace JC, Francis GL et al. · The international journal of biochemistry & cell biology · 1996

   PMID 8930132 · DOI: 10.1016/1357-2725(96)00056-8

2. Preclinical / laboratory research

   IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection.

   Lemmey AB, Martin AA, Read LC et al. · The American journal of physiology · 1991

   PMID 1996625 · DOI: 10.1152/ajpendo.1991.260.2.E213

3. Research publication · design requires review

   Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.

   Crescioli C, Villari D, Forti G et al. · Molecular and cellular endocrinology · 2002

   PMID 12573816 · DOI: 10.1016/s0303-7207(02)00370-2

4. Research publication · design requires review

   Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture.

   Russo VC, Werther GA · Growth factors (Chur, Switzerland) · 1994

   PMID 7779409 · DOI: 10.3109/08977199409011003

5. Preclinical / laboratory research

   IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass.

   Martin AA, Tomas FM, Owens PC et al. · The American journal of physiology · 1991

   PMID 1928375 · DOI: 10.1152/ajprenal.1991.261.4.F626

IGF-1 DES supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

IGF-1 DES for sale: compare prices, sizes and forms from every tracked supplier →

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles